Petros Pharmaceuticals Reports 476% Year-Over-Year Growth of STENDRA Tablet Sales

Nov 3, 2021 By MarketDepth

Biotechnology Business Headlines Healthcare Investing What's Hot


Petros Pharmaceuticals, Inc. (NASDAQ: PTPI) reported a 476% growth year over year of STENDRA tablet sales, part of an exclusive digital health marketing agreement with Hims & Hers Health, Inc., the telehealth platform that focuses on providing personalized health and wellness experiences to consumers.  Additional dosages of STENDRA through the Hims & Hers platform will be available, expanding the partnership.  “Our continued relationship with Hims supports an industry-leading telehealth platform that allows individuals to inquire about and address erectile dysfunction with discretion and by way of a convenient method of healthcare engagement,” said Fady Boctor, Petros Pharmaceuticals’ President and Chief Commercial Officer. “With significant growth year-over-year of STENDRA tablet sales through Hims, we are excited to expand our collaboration with Hims and enhance access to STENDRA through this critical channel.”

“Offering our customers access to STENDRA has helped to strengthen our platform and achieve our mission of providing greater access to personalized care. We are elated to be able to provide help and support to the many people who experience erectile dysfunction. We look forward to expanding our relationship with Petros by providing more dosage options at affordable prices through our platform so that even more people can access high quality, personalized care.”

Dr. Patrick Carroll, Chief Medical Officer at Hims & Hers

“In our exclusive marketing agreement with Hims, Petros continues to support the goal of destigmatizing the request for this therapy and expanding overall engagement for treatment,” concluded Mr. Boctor.